학술논문
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
Document Type
Article
Author
Cramer, Paula ; Fürstenau, Moritz; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fink, Anna-Maria; Fischer, Kirsten; Langerbeins, Petra; Al-Sawaf, Othman; Tausch, Eugen; Schneider, Christof; Schetelig, Johannes; Dreger, Peter; Böttcher, Sebastian; Kreuzer, Karl-Anton; Schilhabel, Anke; Ritgen, Matthias; Brüggemann, Monika; Kneba, Michael; Stilgenbauer, Stephan; Eichhorst, Barbara; Hallek, Michael
Source
In The Lancet Haematology October 2022 9(10):e745-e755
Subject
Language
ISSN
2352-3026